

APPENDIX B

123. An isolated polypeptide of any one of claims 202-203 which is a recombinant polypeptide.
132. A fusion protein comprising a polypeptide of any one of claims 202-203 and an additional amino acid sequence.
133. A fusion protein of claim 132, wherein the additional amino acid sequence comprises an *H. pylori* polypeptide.
149. A composition comprising a polypeptide of any one of claims 202-203 and a pharmaceutically acceptable carrier.
202. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 764, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO: 764.
203. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 764, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO: 764.
212. A composition comprising a fusion protein of claim 132 and a pharmaceutically acceptable carrier.
220. An isolated polypeptide of any one of claims 202-203 comprising at least about 12 consecutive amino acid residues of SEQ ID NO: 764.
221. An isolated polypeptide of any one of claims 202-203 comprising at least about 16 consecutive amino acid residues of SEQ ID NO: 764.

08/487,032

Group Art Unit 1645

222. An isolated polypeptide of any one of claims 202-203 comprising at least about 20 consecutive amino acid residues of SEQ ID NO: 764.

223. An isolated polypeptide of any one of claims 202-203 comprising at least about 50 consecutive amino acid residues of SEQ ID NO: 764.

224. An isolated polypeptide of any one of claims 202-203 comprising at least about 100 consecutive amino acid residues of SEQ ID NO: 764.